Cytosorbents (CTSO) Long-Term Deferred Tax (2018 - 2021)

Cytosorbents' Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $27.2 million for Q4 2021.

• Quarterly Long-Term Deferred Tax rose 7.79% year-over-year to $27.2 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $27.2 million (up 7.79% YoY) and the FY2021 annual result came in at $27.2 million, up 7.79% from the prior year.
• Long-Term Deferred Tax was $27.2 million for Q4 2021 at Cytosorbents, up from $25.2 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $27.2 million in Q4 2021 and bottomed at $21856.0 in Q4 2018.
• A 4-year average of $18.9 million and a median of $24.2 million in 2019 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2019 — Long-Term Deferred Tax soared 106285.61% — and 2021, when it increased 7.79%.
• Cytosorbents' Long-Term Deferred Tax stood at $21856.0 in 2018, then surged by 106285.61% to $23.3 million in 2019, then gained by 8.49% to $25.2 million in 2020, then rose by 7.79% to $27.2 million in 2021.
• Business Quant data shows CTSO's Long-Term Deferred Tax at $27.2 million in Q4 2021, $25.2 million in Q4 2020, and $23.3 million in Q4 2019.